Lemaitre Vascular (LMAT) Cash & Equivalents (2010 - 2026)

Lemaitre Vascular (LMAT) has reported Cash & Equivalents for 17 consecutive years, with $26.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 5.96% year-over-year to $26.9 million; the TTM figure through Mar 2026 stood at $26.9 million (up 5.96% YoY), while the FY2025 annual figure was $28.2 million, up 10.29% from the prior year.
• Cash & Equivalents slipped to $26.9 million in Q1 2026 per LMAT's latest filing, from $28.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $28.2 million in Q4 2025 and bottomed at $15.6 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $22.3 million across 5 years, with a median of $22.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 33.86% — and 2024, when it jumped 59.47%.
• Lemaitre Vascular's Cash & Equivalents stood at $19.1 million in 2022, then gained by 26.84% to $24.3 million in 2023, then increased by 5.53% to $25.6 million in 2024, then climbed by 10.29% to $28.2 million in 2025, then decreased by 4.93% to $26.9 million in 2026.
• Business Quant data shows LMAT's Cash & Equivalents at $26.9 million in Q1 2026, $28.2 million in Q4 2025, and $25.5 million in Q3 2025.